Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies

NCT06577987 is registered in ClinicalTrials.gov with Circle Pharma as lead sponsor.

NCT NCT06577987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06577987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies
Lead sponsor
Circle Pharma
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 14, 2024
Completion date
March 14, 2027
Enrollment
220 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, breast neoplasms, cancer, lung cancer, metastatic solid tumor, neuroendocrine carcinoma, neuroendocrine tumors, rb1 gene mutation, refractory solid tumor, triple negative breast cancer